Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan

Ikeda, Masafumi; Yamamoto, Hiroki; Kaneko, Makiko; Oda, Hiroshi; Takahashi, Hideaki; Umemoto, Kumiko; Watanabe, Kazuo; Hashimoto, Yusuke; Ohno, Izumi; Mitsunaga, Shuichi; Okusaka, Takuji

doi:10.1007/s10147-016-0995-8

Cited by 14 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that there was insufficient screening during the survey years. In fact, presumably insufficient HBV screening has been reported in various countries, including Japan . Ikeda et al reported that among those who had first‐line chemotherapy for malignancy from April 2008 through March 2013, the percentage of patients screened using the HBsAg test was 66.3%, and 19.9% of patients were screened using the anti‐HBs and anti‐HBc tests .…”

Section: Discussionmentioning

confidence: 99%

“…These results were apparently higher than those from our study, especially for the screening rate using HBsAg. Based on the findings from previous studies, whether physicians perform screening tests to prevent HBV reactivation is dependent on the medical facilities . The use of the NDB, which accumulates comprehensive insurance claim data, would be ideal to ascertain the real prevalence of screening to prevent HBV in Japan.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan

Fujita

Sugiyama

Sato

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

This study aimed to determine the incidence and risk factors for hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) undergoing immunosuppressive therapy. The National Database of Japan, in which insurance claim data have been comprehensively accumulated, was utilized. The subjects were 76 641 RA patients who were plausibly initiated on immunosuppressive therapy from April 2013 to March 2014. Laboratory tests of the hepatitis B surface antigen, anti-hepatitis B virus surface antibody, and anti-hepatitis B virus core antibody were performed in 28.23%, 12.52% and 14.63% of patients, respectively, when the therapy was initiated. We found that HBV reactivation and fulminant hepatitis occurred in both the patients with and without HBV DNA monitoring, indicating insufficient monitoring in Japan during the study. The cumulative incidence of HBV reactivation over 24 months was 1.57% (95% confidence interval [CI] = 1.28%-1.92%) in the monitoring group, which consisted of those with resolved HBV infection. Glucocorticoid administration was a potent risk factor for HBV reactivation (hazard ratio [HR] = 1.70, 95% CI = 1.26-2.29, P = .001 in all subjects, and HR = 1.82, 95% CI = 1.18-2.81, P = .007 in the nonmonitoring group), although it was not statistically significant in the monitoring group (HR = 1.49, 95% CI = 0.99-2.26 and P = .057). No significant risk difference was observed between single administration of methotrexate and biological drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan

Fujita

Sugiyama

Sato

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…However, screening rates for infections are insufficient in practice. Surveys of oncologists and rheumatologists in Japan and other countries show low rates of hepatitis B virus (HBV) screening before chemotherapy or immunosuppressive therapy . The risk of HBV reactivation or Mycobacterium tuberculosis reactivation with systemic corticosteroid treatment has been shown in rheumatic and autoimmune diseases, although it has only rarely been investigated in dermatology …”

Section: Introductionmentioning

confidence: 99%

“…Surveys of oncologists and rheumatologists in Japan and other countries show low rates of hepatitis B virus (HBV) screening before chemotherapy or immunosuppressive therapy. [3][4][5][6][7] The risk of HBV reactivation or Mycobacterium tuberculosis reactivation with systemic corticosteroid treatment has been shown in rheumatic and autoimmune diseases, although it has only rarely been investigated in dermatology. [8][9][10][11] There are few guidelines for the screening of infectious diseases before the initiation of immunosuppressive treatments for skin disorders.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of infectious diseases in patients with autoimmune blistering diseases

Ujiie

Yoshimoto

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

A long‐term immunosuppressive treatment can provoke latent infections. Autoimmune blistering diseases (AIBD) are mostly treated with systemic immunosuppressive agents. To prevent the reactivation or exacerbation of existing latent infections, patients must be screened for infectious diseases before immunosuppressive treatments are initiated. However, the prevalence of infectious diseases in AIBD remains to be elucidated. To evaluate the necessity of screening infectious diseases in AIBD, we retrospectively reviewed the clinical records of 215 patients at a single center with AIBD for hepatitis B virus (HBV), hepatitis C virus (HCV), Mycobacterium tuberculosis, Treponema pallidum, human T‐cell leukemia virus type 1 (HTLV‐1) and HIV infections. Approximately 40% of patients were infected with HBV. During systemic corticosteroid treatment, HBV DNA became positive in 3.4% of cases. Antibodies to HCV, interferon‐γ release assays for M. tuberculosis and the T. pallidum latex agglutination test were positive in 0.6%, 6.6% and 1.2% cases, respectively. Neither HTLV‐1 nor HIV infections were detected. In conclusion, checks for HBV and M. tuberculosis infections should be made before immunosuppressive treatments are started, because of the high prevalence of these potentially life‐threatening infections. Other infections should be tested for depending on the patient’s risk factors.

show abstract

“…As discussed above, this region characteristically has a high HBV infection rate [50]. China and South Korea have a higher vaccination rate than Japan (Table 2), and the number of HBV-infected individuals decreased dramatically after the introduction of universal HBV vaccination [43].…”

Section: East Asiamentioning

confidence: 99%

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Sagami

Hibi

2018

Inflamm Intest Dis

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD) patients with immunocompromise have a high risk of developing complications related to viral infections. Western countries were the first to formulate vaccine guideline. Asian countries developed their national and international vaccine guidelines a little later in order to reduce the risk of mortality from viral infections. However, no studies to date have examined the differences in vaccinations that prevail among Asian countries. Summary: This review summarizes the vaccination status and schedules in various Asian countries for immunocompromised IBD patients. Vaccination rates, regardless of the specific vaccine, were high in Japan, South Korea, and China and low in India and the Philippines. Vaccine schedules differed by country, and outbreaks of measles and rubella were seen due to low vaccination rates in Southeast Asia and South Asia. Live vaccines cannot be administered during immunosuppressive treatment. Infection with measles, mumps, and varicella during immunosuppressive therapy carries a high risk of mortality, and thus confirmation of immunization status is recommended as soon as IBD is diagnosed and, when possible, live vaccines should be administered before the initiation of immunosuppressive treatment. In patients seronegative for hepatitis B, administration of the hepatitis B vaccine is also recommended. Key Messages: Physicians, while considering severity of outbreaks, should understand the differences in vaccination status that exist among the various Asian countries and regions.

show abstract

Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan

Cited by 14 publications

References 17 publications

Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan

Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan

Prevalence of infectious diseases in patients with autoimmune blistering diseases

Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease

Contact Info

Product

Resources

About